India’s Affordable Weight-Loss Drugs Poised To Reshape Global Obesity Fight

Obesity has become a global health crisis, with demand for effective weight-loss therapies soaring. India’s pharmaceutical industry is now positioned to disrupt the market by offering affordable alternatives, potentially transforming healthcare access in developing nations.  

Patent Expiry And Market Entry  
The patent on semaglutide, the active ingredient in Novo Nordisk’s Wegovy and Ozempic, expired in India on March 21, 2026. This opens the door for Indian firms such as Sun Pharma and Dr. Reddy’s Laboratories to introduce generic versions. Analysts expect nearly 50 branded generics to enter the market, driving intense competition and lowering costs.   

Impact On Accessibility  
Currently, weight-loss injections cost thousands of dollars annually in Western markets, limiting access to wealthier populations. India’s generics could slash prices by half or more, enabling broader adoption across Asia, Africa, and Latin America. This democratization of treatment could significantly reduce obesity-related health burdens.  

Global Implications  
India’s move challenges multinational pharmaceutical giants by reshaping pricing dynamics. Affordable generics will not only expand treatment access but also accelerate innovation and competition in the obesity drug market. Experts believe this could redefine global strategies for tackling obesity and metabolic disorders.  

Key Highlights  

• Semaglutide patent expired in India in March 2026  
• Indian firms set to launch up to 50 generics  
• Prices expected to fall by more than 50%  
• Affordable access to Wegovy and Ozempic alternatives  
• Potential to reshape global obesity treatment landscape  

Sources: Yahoo Finance, NDTV, MSN